The Protective Effect of Poloxamer-188 on Platelet Functions

Nil Guler1, Schuharazad Abro1, Marty Emanuele2

  • 11 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.

Abstract

Insights

Poloxamer-188 (MST-188) effectively preserves platelet function by protecting against ADP- and collagen-induced aggregation. This finding suggests MST-188 can enhance platelet viability during storage.

Area of Science:

  • Biomedical Science
  • Hematology
  • Cell Biology

Background:

  • Poloxamer-188 (MST-188) demonstrates efficacy in repairing damaged cell membranes and protecting blood cell viability.
  • MST-188 is investigated for its potential to extend the functional lifespan of platelets.

Purpose of the Study:

  • To evaluate the hypothesis that MST-188 can prolong platelet function duration.
  • To assess the protective effects of MST-188 on platelet aggregation.

Main Methods:

  • Blood samples from 20 healthy volunteers were used to prepare platelet-rich plasma (PRP).
  • MST-188 was added to whole blood (WBP) or PRP (PRPP) at 2 or 10 mg/mL concentrations.
  • Agonist-induced aggregation (AIA) was measured at 30, 180, and 300 minutes using Adenosine diphosphate (ADP), collagen, and other agonists.

Main Results:

  • MST-188 exhibited a protective effect on ADP- and collagen-induced platelet aggregation.
  • At 300 minutes, ADP AIA was significantly higher with MST-188 compared to saline controls.
  • Significant protection was observed for both ADP and collagen aggregation across WBP and PRPP preparations over time.

Conclusions:

  • MST-188 demonstrates protective effects against ADP- and collagen-induced platelet aggregation.
  • These findings suggest MST-188 can contribute to preserving platelet functionality during storage in blood banks.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.4K